PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Both companies show declining cash positions (-3.88% vs GNPX's -15.10%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half of GNPX's -15.10%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Similar to GNPX's -10.68%. Walter Schloss would confirm standard short-term asset patterns.
-4.12%
Below half of GNPX's -14.86%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-3.46%
Below half GNPX's -17.62%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x GNPX's -1.23%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-3.14%
≥ 1.5x GNPX's -0.73%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Below half of GNPX's -13.36%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.45%
Above 1.5x GNPX's 0.08%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
25.40%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
-25.40%
Less than half of GNPX's 20.60%. David Dodd sees fewer expansions in other current obligations.
32.92%
Above 1.5x GNPX's 14.09%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Less than half of GNPX's 14.09%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
0.5-0.75x GNPX's -6.84%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
0.5-0.75x GNPX's -15.19%. Martin Whitman is wary of lagging equity growth vs. competitor.
-4.09%
Below half GNPX's -13.36%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
3.93%
Less than half of GNPX's 15.10%. David Dodd sees better deleveraging or stronger cash buildup than competitor.